Nasser Hanna

  • 8113 Citations
  • 41 h-Index
19992020

Research output per year

If you made any changes in Pure these will be visible here soon.

Publications

Filter
Letter
2020

The case for maintenance pemetrexed plus bevacizumab

Hanna, N. & Jalal, S., Mar 1 2020, In : Journal of Clinical Oncology. 38, 7, p. 770-771 2 p.

Research output: Contribution to journalLetter

1 Scopus citations
2018

Reply to M.E.H.M. Van Hoef

Hanna, N., Temin, S., Oliver, T. K. & Masters, G., Feb 1 2018, In : Journal of Clinical Oncology. 36, 4, 1 p.

Research output: Contribution to journalLetter

Reply to the letter to the editor 'A centralised multidisciplinary clinic approach for germ cell tumours' by Crawford

Albany, C., Adra, N., Snavely, A., Cary, C., Masterson, T., Foster, R., Kesler, K., Ulbright, T., Cheng, L., Chovanec, M., Taza, F., Hanna, N. & Einhorn, L., Jan 1 2018, In : Annals of Oncology. 29, 11, p. 2264-2265 2 p.

Research output: Contribution to journalLetter

2006

In reply [8]

Hanna, N. H., Nov 10 2006, In : Journal of Clinical Oncology. 24, 32, p. 5175-5176 2 p.

Research output: Contribution to journalLetter

3 Scopus citations
2005

Responsiveness to cetuximab without mutations in EGFR [3]

Tsuchihashi, Z., Khambata-Ford, S., Hanna, N. & Jänne, P. A., Jul 14 2005, In : New England Journal of Medicine. 353, 2, p. 208-209 2 p.

Research output: Contribution to journalLetter

107 Scopus citations
2001

Diagnostic and therapeutic quandaries in a patient with a germ cell tumor

Hanna, N., Kesler, K. & Einhorn, L., Oct 15 2001, In : Journal of Clinical Oncology. 19, 20, 1 p.

Research output: Contribution to journalLetter